Needham & Company Raises Price Target on Fabrinet (FN) to $32 Post 4Q Beat and Raise

Go back to Needham & Company Raises Price Target on Fabrinet (FN) to $32 Post 4Q Beat and Raise

Fabrinet (FN) Growth Accelerating on Optical Upgrades - PiperJaffray

February 2, 2016 8:36 AM EST

Piper Jaffray analyst, Troy Jensen, thinks that the theme of growth in optical communications (driven by 100G Datacom and telecom upgrades) is showing signs of significant acceleration after Fabrinet's (NYSE: FN) earnings results. No change to Overweight rating but the price target increases to $33 from $29.

Fabrinet reported an outstanding quarter with revenues, margins and EPS all coming in above consensus estimates,... More

Fabrinet (FN) Tops Q2 EPS by 4c, Q3 Guidance Tops Views

February 1, 2016 4:21 PM EST

Fabrinet (NYSE: FN) reported Q2 EPS of $0.50, $0.04 better than the analyst estimate of $0.46. Revenue for the quarter came in at $233 million versus the consensus estimate of $220.75 million.

GUIDANCE:

Fabrinet sees Q3 2016 EPS of $0.52-$0.54, versus the consensus of $0.45. Fabrinet sees Q3... More

Piper Jaffray Anticipates Strong Results for Fabrinet's (FN) 2Q - Reiterates Outperform

February 1, 2016 8:21 AM EST

Piper Jaffray reiterated an Overweight rating and $29.00 price target on Fabrinet (NYSE: FN) ahead of the company's 2Q earnings report. Fabrinet is slated to report results after the close on February 1. Piper Jaffray anticipates that the company will beat consensus and guide up for the March quarter.... More

Trading Radar for 2/1: Alphabet (GOOG), Aetna (AET), Sysco (SYY), General Growth (GGP), Mattel (MAT) Report

January 29, 2016 3:39 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:30am EST

PCE Prices: - no Street consensusPersonal Income - no Street consensusPersonal Spending - no Street consensus

Earnings:

Aetna (NYSE: AET) - consensus EPS $1.21
Cardinal Health (NYSE: CAH) - consensus EPS $1.26
Changyou.com (Nasdaq:... More